<DOC>
	<DOCNO>NCT01805362</DOCNO>
	<brief_summary>Objective : To show frequency aldosterone breakthrough low RAS blocker give bedtime compare awaking , analyze determinant consequence aldosterone breakthrough . Duration study : Inclusion 2 year , follow-up one year , total 3 year Design : prospective , multicenter , randomize , control , open label , two parallel group . Main selection criterion : Inclusion criterion - Chronic kidney disease stage 3 4 , - ACEI ( captopril , enalapril , ramipril ) , and/or ARB ( losartan , valsartan , irbesartan ) awake least three month , - History hypertension proteinuria &gt; 0,5 g/24h g/g créatininurie . Exclusion criterion - Office blood pressure ≥ 160/100 mmHg , - Anti-aldosterone ( spironolactone , eplerenone ) potassium spar diuretic ( modamide , amiloride ) , direct renin inhibitor . Evaluation criterion : Primary : Serum aldosterone level one year . Secondary : - Serum aldosterone/renin ratio , - 24h urine aldosterone , - Significant aldosterone breakthrough define &gt; 10 % increase serum aldosterone level baseline value , - Aldosterone breakthrough define increase serum aldosterone level baseline value , - HbA1c , - Urinary albumin/creatinine ratio ( UACR ) spot morning urine sample , - Systolic home blood pressure ( SBP ) , - Estimated glomerular filtration rate ( eGFR ) use MDRD equation .</brief_summary>
	<brief_title>RAS Blockade Bedtime Versus Awakening Aldosterone Breakthrough</brief_title>
	<detailed_description>Rational : Serum aldosterone level may increase despite blockade renin angiotensin system ( RAS ) angiotensin convert enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) . This aldosterone breakthrough might associate bad outcome : leave ventricular hypertrophy , proteinuria progression renal failure . Antihypertensive drug give either awake bedtime . RAS stimulate nighttime . RAS blocker diuretic give awake may stimulate aldosterone synthesis , favor aldosterone breakthrough . Objective : To show frequency aldosterone breakthrough low RAS blocker give bedtime compare awaking , analyze determinant consequence aldosterone breakthrough . Duration study : Inclusion 2 year , follow-up one year , total 3 year Design : prospective , multicenter , randomize , control , open label , two parallel group .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Chronic kidney disease stage 3 4 , ACEI ( captopril , enalapril , ramipril ) , and/or ARB ( losartan , valsartan , irbesartan ) awake least three month , History hypertension proteinuria &gt; 0,5 g/24h g/g creatininuria , Adult social security insurance , Informed consent sign . Office blood pressure ≥ 160/100 mmHg , Pathology life expectancy &lt; 1 year , Antialdosterone ( spironolactone , eplerenone ) potassium spar diuretic ( modamide , amiloride ) , direct renin inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>